Article ID Journal Published Year Pages File Type
10911016 Lung Cancer 2014 6 Pages PDF
Abstract
Our results indicate that advanced NSCLC patients with positive expression of EZH2 exhibited resistance to cisplatin-based chemotherapy. EZH2 may be a predictive and prognostic factor for cisplatin-based therapy response and disease survival in advanced NSCLC.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy
Authors
, , , , , , ,